Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.

Anti-cancer drugs - 1 Sept 2015

Mazumdar Tuhina, Sen Banibrata, Wang Yifan, Peng Shaohua, Nicholas Courtney, Glisson Bonnie S, Myers Jeffrey N, Johnson Faye M

Abstract excerpt

Treatments for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have limited efficacy. One potential therapeutic target for HNSCC is the RAS/RAF/MEK/ERK cascade, which is one of the major signaling pathways for HNSCC cell survival. In HNSCC, RAS can be activated either by HRAS mutation or by upstream signaling. The ABL inhibitor nilotinib acts as a weak RAF inhibitor that induces RAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Heterografts

Share to Neoplasm Transplantation

Share to Neoplasms, Squamous Cell

Share to Proto-Oncogene Proteins c-raf

Share to raf Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26053277
DOI: 10.1097/CAD.0000000000000251
PMCID: PMC4515205

Genes

BRAF
HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.PMID 26053277Read ↗

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.Semantic proximity Read ↗

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.Semantic proximity Read ↗

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Semantic proximity Read ↗

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Semantic proximity Read ↗

Mutant HRAS as novel target for MEK and mTOR inhibitors.Semantic proximity Read ↗

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.Semantic proximity Read ↗

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.Semantic proximity Read ↗

Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.